Accolade (ACCD) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a chan ...

SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York on Thursday, September 5 at 9:15 am ET. A webcast will be available at ir.accolade.com and a replay will be available for 90 days. About Accolade, Inc. Accolade (Nasdaq: ACCD) is a Personalized Healthcare company that provides millions of people and their families with exceptional healthcare experiences so they can live ...

LITTLE ROCK, Ark., Aug. 22, 2024 /PRNewswire/ -- Celeste Health Solutions (Celeste), a new company that will focus on merging the power of data insights, technology and personalized health management, is being introduced to the market to simplify healthcare access for employees while also easing the burden for employers.According to Bryan Dorathy, Celeste's Vice President of Innovation, Celeste will appeal to employers who want to see their employees' health improve while also helping them better navigate t ...

SEATTLE, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase in Boston on Wednesday, August 14 at 12:00 pm ET. A webcast will be available at ir.accolade.com and a replay will be available for 90 days. About Accolade, Inc. Accolade (Nasdaq: ACCD) is a Personalized Healthcare company that provides millions of people and their families with exceptional healthcare experiences ...

Accolade (ACCD) has been beaten down lately with too much selling pressure. While the stock has lost 47% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measur ...

Accolade (ACCD) has been on a downward spiral lately with significant selling pressure. After declining 47% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is ove ...

NEW YORK, July 09, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. (“Accolade” or “the Company”) (NASDAQ: ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ACCD. Investigation Details On June 27, 2024, Accolade reported a quarterly loss of $0.35 per share. Following its earnings re ...

ipopba Elevator Pitch I have a Hold investment rating for Accolade, Inc. (NASDAQ:ACCD) stock. My prior April 5, 2024 write-up drew attention to Accolade's latest corporate developments like the addition of new partners. The current update reviews ACCD's Q1 FY 2025 (YE February 28, 2025) financial performance and evaluates the company's financial prospects. Accolade's Q1 results benefited from a favorable timing difference, but its updated full-year guidance was mixed. ACCD lowered its FY 2025 top line guida ...

Accolade, Inc. (NASDAQ:ACCD) Q1 2025 Earnings Conference Call June 27, 2024 4:30 PM ET Company Participants Todd Friedman - SVP of IR Rajeev Singh - CEO Steve Barnes - CFO Conference Call Participants Richard Close - Canaccord Genuity Craig Hettenbach - Morgan Stanley Michael Cherny - Leerink Partners Jeff Garro - Stephens Inc. Ryan Daniels - William Blair Jailendra Singh - Truist Securities Jessica Tassan - Piper Sandler Ryan MacDonald - Needham & Company Stephanie Davis - Barclays Stan Berenshteyn ...

Group 1 - Accolade reported a quarterly loss of $0.35 per share, better than the Zacks Consensus Estimate of a loss of $0.48, and improved from a loss of $0.52 per share a year ago, indicating an earnings surprise of 27.08% [1] - The company generated revenues of $110.47 million for the quarter ended May 2024, exceeding the Zacks Consensus Estimate by 5.20%, and up from $93.23 million in the same quarter last year [1] - Accolade has surpassed consensus EPS estimates and revenue estimates four times over the last four quarters [1] Group 2 - Accolade shares have declined approximately 49% since the beginning of the year, contrasting with the S&P 500's gain of 14.9% [2] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for investors [2] - The estimate revisions trend for Accolade is currently favorable, resulting in a Zacks Rank 2 (Buy) for the stock, suggesting expected outperformance in the near future [3] Group 3 - The current consensus EPS estimate for the upcoming quarter is -$0.44 on revenues of $112.94 million, and for the current fiscal year, it is -$1.23 on revenues of $490.58 million [4] - The Technology Services industry, to which Accolade belongs, is currently ranked in the top 23% of over 250 Zacks industries, indicating a favorable outlook [4]